MENU
+Compare
GYRE
Stock ticker: NASDAQ
AS OF
Jan 14 closing price
Price
$7.69
Change
-$0.10 (-1.28%)
Capitalization
740.8M

GYRE stock forecast, quote, news & analysis

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis... Show more

GYRE
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. GYRE showed earnings on November 07, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for GYRE with price predictions
Jan 13, 2026

GYRE in +5.27% Uptrend, advancing for three consecutive days on January 13, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GYRE advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GYRE's RSI Indicator exited the oversold zone, of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where GYRE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 07, 2026. You may want to consider a long position or call options on GYRE as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GYRE just turned positive on January 07, 2026. Looking at past instances where GYRE's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

GYRE moved above its 50-day moving average on January 12, 2026 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on December 18, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GYRE broke above its upper Bollinger Band on January 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GYRE entered a downward trend on January 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.267) is normal, around the industry mean (30.106). P/E Ratio (192.250) is within average values for comparable stocks, (51.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.888). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (6.515) is also within normal values, averaging (322.270).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 114.05B. VRTX holds the highest valuation in this group at 114.05B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 45%. MREO experienced the highest price growth at 70%, while ATRA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -7%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was 26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 81
Price Growth Rating: 59
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
GYRE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
12770 High Bluff Drive
Phone
+1 619 949-3681
Employees
4
Web
https://www.gyretx.com